Experienced in Alveolar Soft Part Sarcoma

Dr. Nicholas J. Vogelzang

Hematology Oncology
3730 S Eastern Ave, 
Las Vegas, NV 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Alveolar Soft Part Sarcoma
3730 S Eastern Ave, 
Las Vegas, NV 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nicholas Vogelzang is a Hematologist Oncology provider in Las Vegas, Nevada. Dr. Vogelzang is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, Orchiectomy, and Nephrectomy.

His clinical research consists of co-authoring 211 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in NV
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

3730 S Eastern Ave, Las Vegas, NV 89169

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Biological
Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody
Study Phase: Phase 1
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Procedure, Other, Biological
Study Drugs: Pembrolizumab, Recombinant EphB4-HAS Fusion Protein
Study Phase: Phase 2
A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drugs: SRF617, Etrumadenant, Zimberelimab
Study Phase: Phase 2
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drugs: TP-1454 Alone, TP-1454 Combination Therapy
Study Phase: Phase 1
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ladiratuzumab Vedotin
Study Phase: Phase 2
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Tazemetostat, Abiraterone/prednisone, Enzalutamide
Study Phase: Phase 1/Phase 2
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: TP-1287
Study Phase: Phase 1
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: June 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
Enrollment Status: Terminated
Publish Date: May 21, 2024
Intervention Type: Drug
Study Drug: ABM-1310
Study Phase: Phase 1
A Multicentre Phase 2b Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment With a Taxane
A Multicentre Phase 2b Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment With a Taxane
Enrollment Status: Completed
Publish Date: April 17, 2024
Intervention Type: Drug
Study Drugs: Docetaxel, ModraDoc006/r
Study Phase: Phase 2
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2024
Intervention Type: Drug
Study Drugs: Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Study Phase: Phase 2
An Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC Who Failed Either Abiraterone or Enzalutamide
An Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC Who Failed Either Abiraterone or Enzalutamide
Enrollment Status: Completed
Publish Date: February 12, 2024
Intervention Type: Drug
Study Drug: GT0918
Study Phase: Phase 2
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drugs: CPI-006 Anti-CD73 Antibody, Ciforadenant, Pembrolizumab
Study Phase: Phase 1
A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Combination product
Study Drugs: Enzalutamide, Abiraterone, Apalatumide
Study Phase: Phase 1
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Enrollment Status: Completed
Publish Date: December 29, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1/2, Multi-Center, Open-Label, Two-Stage Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Phase 1/2, Multi-Center, Open-Label, Two-Stage Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of A Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 In Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (MCRPC)
A Phase 1 Study of A Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 In Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (MCRPC)
Enrollment Status: Completed
Publish Date: February 07, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Enrollment Status: Completed
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 21 Less Clinical Trials

209 Total Publications

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 29, 2025
Similar Doctors
Experienced in Alveolar Soft Part Sarcoma
Dr. Anuradha R. Thummala
Hematology Oncology | Hematology | Oncology
Experienced in Alveolar Soft Part Sarcoma
Dr. Anuradha R. Thummala
Hematology Oncology | Hematology | Oncology

Allison Curtis Kingsley Meoz Michael And Sanchez PC

7445 Peak Dr, 
Las Vegas, NV 
 (9.8 miles away)
702-952-2140
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anuradha Thummala is a Hematologist Oncology specialist and a Hematologist in Las Vegas, Nevada. Dr. Thummala is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Lung Cancer, and Iron Deficiency Anemia.

Experienced in Alveolar Soft Part Sarcoma
Dr. Vikas K. Gupta
Hematology Oncology | Hematology | Oncology
Experienced in Alveolar Soft Part Sarcoma
Dr. Vikas K. Gupta
Hematology Oncology | Hematology | Oncology

Allison Curtis Kingsley Meoz Michael And Sanchez PC

9280 W Sunset Rd, Suite 100, 
Las Vegas, NV 
 (10.4 miles away)
702-952-1251
Languages Spoken:
English
See accepted insurances

Vikas Gupta is a Hematologist Oncology specialist and a Hematologist in Las Vegas, Nevada. Dr. Gupta is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Protein C Deficiency, Hereditary Resistance to Anti-Vitamin K, Protein S Deficiency, and Congenital Antithrombin 3 Deficiency.

Experienced in Alveolar Soft Part Sarcoma
Dr. Hamidreza Sanatinia
Hematology Oncology | Hematology | Oncology
Experienced in Alveolar Soft Part Sarcoma
Dr. Hamidreza Sanatinia
Hematology Oncology | Hematology | Oncology

Allison Curtis Kingsley Meoz Michael And Sanchez PC

9280 W Sunset Rd, Suite 100, 
Las Vegas, NV 
 (10.4 miles away)
702-952-1251
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hamidreza Sanatinia is a Hematologist Oncology specialist and a Hematologist in Las Vegas, Nevada. Dr. Sanatinia is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Paget Disease of the Breast, Agranulocytosis, Chronic Familial Neutropenia, and Acute Mountain Sickness.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vogelzang's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 7 Advanced Conditions
View All 54 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile